D. Klingbiel
AuthID: R-00J-F96
1
TÃTULO: Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive early breast cancer (HER2+eBC): Interim analysis of the open-label, randomised cross-over PHranceSCa study
AUTORES: O'Shaughnessy, J; Sousa, SP; Cruz, J; Fallowfield, LJ; Auvinen, P; Pulido, C; Cvetanovic, A; Wilks, S; Ribeiro, L; Burotto, M; Klingbiel, D; Messeri, D; Alexandrou, A; Trask, P; Fredriksson, J; Stamatovic, L;
PUBLICAÇÃO: 2020, FONTE: ESMO Breast Cancer Virtual Meeting in ANNALS OF ONCOLOGY, VOLUME: 31
AUTORES: O'Shaughnessy, J; Sousa, SP; Cruz, J; Fallowfield, LJ; Auvinen, P; Pulido, C; Cvetanovic, A; Wilks, S; Ribeiro, L; Burotto, M; Klingbiel, D; Messeri, D; Alexandrou, A; Trask, P; Fredriksson, J; Stamatovic, L;
PUBLICAÇÃO: 2020, FONTE: ESMO Breast Cancer Virtual Meeting in ANNALS OF ONCOLOGY, VOLUME: 31
INDEXADO EM: 
WOS
WOS